Eligibility, compliance and persistence of extended adjuvant endocrine therapy for breast cancer

Acta Oncologica

Volumn 51, Issue 2, 2012, Pages 247-253

  Myrick, Mary E ^a   Schmid, Seraina M ^a,b   Kilic, Nerbil ^a,b   Güth, Uwe ^a,b,c  

^a UNIVERSITY HOSPITAL BASEL   (Switzerland)

^b UHB   (Switzerland)

^c CANTONAL HOSPITAL WINTERTHUR   (Switzerland)

Author keywords

[No Author keywords available]

Indexed keywords

AROMATASE INHIBITOR; HORMONE; TAMOXIFEN;

ADULT; AGED; ARTICLE; BREAST CANCER; CANCER ADJUVANT THERAPY; CANCER HORMONE THERAPY; DISEASE SEVERITY; DRUG WITHDRAWAL; FEMALE; FOLLOW UP; HUMAN; MAJOR CLINICAL STUDY; PATIENT COMPLIANCE; PATIENT SELECTION; PRACTICE GUIDELINE; PRIORITY JOURNAL; TREATMENT DURATION; UNSPECIFIED SIDE EFFECT;

ADULT; AGED; ANTINEOPLASTIC AGENTS, HORMONAL; BREAST NEOPLASMS; CHEMOTHERAPY, ADJUVANT; ELIGIBILITY DETERMINATION; FEMALE; FOLLOW-UP STUDIES; HUMANS; LONG-TERM CARE; MIDDLE AGED; PATIENT COMPLIANCE; PRACTICE GUIDELINES AS TOPIC; RETROSPECTIVE STUDIES; TAMOXIFEN; TREATMENT OUTCOME;

EID: 84856414204     PISSN: 0284186X     EISSN: 1651226X     Source Type: Journal    
DOI: 10.3109/0284186X.2011.619567     Document Type: Article

References (22)

1. Dodwell D, Williamson D. Beyond tamoxifen: Extended and late extended endocrine therapy in postmenopausal early breast cancer. Cancer Treat Rev 2008;34:137-44.
2. Goss PE, Muss HB, Ingle JN, Whelan TJ, Wu M. Extended adjuvant endocrine therapy in breast cancer: Current status and future directions. Clin Breast Cancer 2008;8:411-7.
3. Josefsson ML, Leinster SJ. Aromatase inhibitors versus tamoxifen as adjuvant hormonal therapy for oestrogen sensitive early breast cancer in post-menopausal women: Metaanalyses of monotherapy, sequenced therapy and extended therapy. Breast 2010;19:76-83.
4. Snoj N, Paridaens R, Cufer T. Current controversies in extended adjuvant endocrine therapy for early breast cancer. Curr Opin Oncol 2008;20:627-33.
5. Burstein HJ, Griggs JJ, Prestrud AA, Temin S. American society of clinical oncology clinical practice guideline update on adjuvant endocrine therapy for women with hormone receptor-positive breast cancer. J Oncol Pract 2010;6:243-6.
6. Chlebowski RT, Geller ML. Adherence to endocrine therapy for breast cancer. Oncology 2006;71:1-9.
7. Hadji P. Improving compliance and persistence to adjuvant tamoxifen and aromatase inhibitor therapy. Crit Rev OncolHematol 2010;73:156-66.
8. Edge S, Byrd D, Compton CC, Fritz AG, Greene FL, Trotti A, editors. AJCC cancer staging manual. 7th ed. New York: Springer; 2009.
9. Sobin L, Gospodarowicz M, Wittekind C, editors. UICC: TNM classifi cation of malignant tumors. 7th ed. Oxford: Wiley-Blackwell; 2009.
10. Goldhirsch A, Wood WC, Gelber RD, Coates AS, Th ü rlimann B, Senn HJ. Progress and promise: Highlights of the international expert consensus on the primary therapy of early breast cancer 2007. Ann Oncol 2007;18:1133-44.
11. Andrade SE, Kahler KH, Frech F, Chan KA. Methods for evaluation of medication adherence and persistence using automated databases. Pharmacoepidemiol Drug Saf 2006;15: 565 - 74; discussion 575-7.
12. Barron TI, Connolly R, Bennett K, Feely J, Kennedy MJ. Early discontinuation of tamoxifen: A lesson for oncologists. Cancer 2007;109:832-9.
13. Osterberg L, Blaschke T. Adherence to medication. N Engl J Med 2005;353:487-97.
14. Coates AS, Keshaviah A, Thurlimann B, Mouridsen H, Mauriac L, Forbes JF, et al. Five years of letrozole compared with tamoxifen as initial adjuvant therapy for postmenopausal women with endocrine-responsive early breast cancer: Update of study BIG 1-98. J Clin Oncol 2007;25:486-92.
15. G oss PE, Ingle JN, Martino S, Robert NJ, Muss HB, Piccart MJ, et al. Randomized trial of letrozole following tamoxifen as extended adjuvant therapy in receptor-positive breast cancer: Updated fi ndings from NCIC CTG MA.17. J Natl Cancer Inst 2005;97:1262-71.
16. Jakesz R, Greil R, Gnant M, Schmid M, Kwasny W, Kubista E, et al. Extended adjuvant therapy with anastrozole among postmenopausal breast cancer patients: Results from the randomized Austrian Breast and Colorectal Cancer Study Group Trial 6a. J Natl Cancer Inst 2007;99:1845-53.
17. Mamounas EP, Jeong JH , Wickerham DL, Smith RE, Ganz PA, Land SR, et al. Benefi t from exemestane as extended adjuvant therapy after 5 years of adjuvant tamoxifen: Intention-to-treat analysis of the National Surgical Adjuvant Breast and Bowel Project B-33 trial. J Clin Oncol 2008;26:1965-71.
18. Goldhirsch A, Ingle JN, Gelber RD, Coates AS, Thurlimann B, Senn HJ. Thresholds for therapies: Highlights of the St Gallen International Expert Consensus on the primary therapy of early breast cancer 2009. Ann Oncol 2009;20: 1319-29.
19. Guth U, Huang DJ, Schotzau A, Zanetti-Dä l lenbach R, Holzgreve W, Bitzer J, et al. Target and reality of adjuvant endocrine therapy in postmenopausal patients with invasive breast cancer. Br J Cancer 2008;99:428-33.
20. Hong S, Didwania A, Olopade O, Ganschow P. The expanding use of third-generation aromatase inhibitors: What the general internist needs to know. J Gen Intern Med 2009; 24(Suppl 2):S383 - 8.
21. Hershman DL, Kushi LH, Shao T, Buono D, Kershenbaum A, Tsai WY, et al. Early discontinuation and nonadherence to adjuvant hormonal therapy in a cohort of 8,769 earlystage breast cancer patients. J Clin Oncol 2010;28:4120-8.
22. Ziller V, Kalder M, Albert US, Holzhauer W, Ziller M, Wagner U, et al. Adherence to adjuvant endocrine therapy in postmenopausal women with breast cancer. Ann Oncol 2009;20:431-6